Media and Investors Resources

Press Release, 8 March 2024

Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

Presentation at CG 2024 Musculoskeletal Conference

12 Feb 2024

Press Release, 1 February 2024

Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

Press Release, 31 January 2024

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

Press Release, 4 January 2024

Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA

Press Release, 27 December 2023

Adhoc Press Release

Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA